Lupa Bio, Inc.

2:15 PM - 2:30 PM (EDT), Tuesday, October 22, 2019 ・ 2nd Floor
Lupa Bio is rapidly advancing a Phase-1 ready orally-delivered compound. Our therapeutic approach has broad potential of anti-inflammatory applications, but we’ve put together a streamlined development plan with our sights set first on oligoarticular juvenile idiopathic arthritis (orphan designation, pediatric voucher eligible)… and believe that the safety profile of our compound will justify going into this group, where there are currently no approved disease-modifying therapies.

We have a compelling pre-clinical data package, a full non-clinical tox package, and our compound has already been tested in 3 human studies for an unrelated disease, with safety demonstrated and no adverse events at 20 grams per day, the highest dose tested.

We are now preparing for our pre-IND meeting, which is planned for December this year, and are actively discussing with teams interested in an investment opportunity to advance the program/platform.
Company Type:
Company Website:
Company HQ State:
Company HQ Country:
United States
Year Founded:
Main Therapeutic Focus:
Lead Product in Development:
Lupa-1; lead candidate planning for pre-IND meeting
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):